Tech Stock News
Tuesday, March 28, 2023
Arbutus Biopharma Corp (NASDAQ: ABUS) and Vaccitech PLC – ADR (NASDAQ: VACC) have entered into a partnership to carry out a clinical trial. As part of the agreement, the companies will implement therapeutic combinations to treat patients suffering from chronic hepatitis B virus (HBV) infection (CHB). Additionally, patients who are […]
About 27 million people worldwide could be suffering from chronic HBV infection, and only 4.5 million are on treatment. Today’s treatment options include nucleos and pegylated interferon regimens. Unfortunately, only about 5% or less of these patients are cured by these current treatment options, while the rest have to take […]
Arbutus Biopharma Corp (NASDAQ: ABUS) is back in the news. First, the company announced that it had received a go-ahead from the U.S. Food and Drug Administration to investigate New Drug (IND) application for AB-729 in a Phase 2a clinical trial. The Phase 2a proof-of-concept clinical trial will evaluate the […]
Arbutus Biopharma Corp (NASDAQ: ABUS) has announced that it has recently joined hands with Antios Therapeutics. The two companies have entered into a clinical collaboration is to evaluate a triple combination of Arbutus’ proprietary GalNAc delivered RNAi therapeutic, AB-729, Antios’ proprietary active site polymerase inhibitor nucleotide (ASPIN), ATI-2173, and Viread […]
Arbutus Biopharma Corp (NASDAQ: ABUS) today announced the demonstration of five summaries at the European Association for the Study of the Liver (EASL) International Liver CongressTM (ILC). Summaries presented by Professor Man-Fung Yuen The synopses encompassed an oral late-breaker validation (Demonstration LBO-2764) by Professor Man-Fung Yuen, D.Sc., M.D., Ph.D., and […]